Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity-Reference-Cited by-同舟云学术

Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity

Published:2021-09-11 Issue:1 Volume:63 Page:235-238
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

El Hussein Siba¹²^ORCID,Hu Shimin²,Fang Hong²,Garces Sofia²,Muzzafar Tariq²,Wang Sa A.²,Medeiros L. Jeffrey²,Bueso-Ramos Carlos²,Jelloul Fatima Zahra²

Affiliation:

1. Department of Pathology, The University of Rochester Medical Center, Rochester, NY, USA

2. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1978089

Reference16 articles.

1. Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities

2. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype

3. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

4. Well-differentiated systemic mastocytosis*1A new disease variant with mature mast cell phenotype and lack of codon 816 c-Kit mutations

5. Complete Response After Imatinib Mesylate Therapy in a Patient With Well-Differentiated Systemic Mastocytosis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid sarcoma: An overview;Seminars in Diagnostic Pathology;2023-05

2. Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update;Cancers;2022-07-17